University of Nottingham-ko ikertzaileekin lankidetzan egindako argitalpenak (23)

2024

  1. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 6, pp. 752-759

2023

  1. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  2. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Correction to: Pain and sedation management and monitoring in pediatric intensive care units across Europe: an ESPNIC survey (Critical Care, (2022), 26, 1, (88), 10.1186/s13054-022-03957-7)

    Critical Care

  2. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

  3. Pain and sedation management and monitoring in pediatric intensive care units across Europe: an ESPNIC survey

    Critical Care, Vol. 26, Núm. 1

2020

  1. 2018 updated European League against Rheumatism evidence-based recommendations for the diagnosis of gout

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 1, pp. 31-38

2019

  1. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

2017

  1. 2016 updated EULAR evidence-based recommendations for the management of gout

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 29-42

  2. Treat-To-Target (T2T) recommendations for gout

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 4, pp. 632-638

2015

  1. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1

    American Journal of Medical Genetics, Part A, Vol. 167, Núm. 2, pp. 296-312

  2. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 10010, pp. 2287-2323

  3. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 9995, pp. 743-800

2014

  1. Improving cardiovascular and renal outcomes in gout: What should we target?

    Nature Reviews Rheumatology, Vol. 10, Núm. 11, pp. 654-661

  2. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia

    BMJ Open, Vol. 4, Núm. 7

  3. Up-titration of allopurinol in patients with gout

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 1, pp. 25-30

2012

  1. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  2. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196

2011

  1. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 4, pp. 571-575

  2. European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 4, pp. 563-570